UNSPSC 51151630: Deptropine or dibenzheptropine

This classification denotes a tropane with the molecular formula C23H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AY31301GKG, chemically known as 8-azabicyclo(3.2.1)octane, 3-((10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-yl)oxy)-8-methyl-, endo- but generally known as deptropine, which bears US NIH Compound Identifier 16576. European Medicines Agency schedules Deptropine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06984MIG.

World Health Organization schedules deptropine in its Anatomical Therapeutic Chemical (ATC) Classification. DEPTROPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1CC2N(C(CC2)C1)C)C1C2C(CCC3C1CCCC3)CCCC2.

UNSPSC 51151630 Deptropine or dibenzheptropine is a Commodity code whose recent state and local activity centers on procurement of naloxone and related drug-response or pharmaceutical management systems rather than the specific chemical compound the code nominally describes. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual supplies of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the county's community health building; the Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to solicit vendor capabilities for a direct-to-manufacturer prescription program serving state pharmacy benefit needs. The issuing bodies reflect a mix of county health departments and state health agencies pursuing pharmaceutical supply and program-management solutions. The recent opportunities show activity in Florida and Texas, with the solicitations targeting community health initiatives and state-level pharmacy benefit administration rather than the narrow chemical-compound scope the code name suggests.

Seminole County's IFB closed July 26, 2023, requiring vendors to submit unit pricing and comply with E-Verify, drug-free workplace certification, and insurance requirements including workers' compensation and commercial general liability, with a two-year initial term and one-year renewal option. The Texas RFI, with a response deadline of April 3, 2026, sought information on vendors' capacity for direct contracting with self-insured health plans and state agencies using negotiated net pricing models outside traditional pharmacy benefit manager or group purchasing organization channels. The code shows limited recent state and local activity and appears to carry a nominal scope misalignment — the recent opportunities are primarily naloxone and pharmaceutical-program solicitations rather than purchases of deptropine or dibenzheptropine specifically, suggesting business development professionals should verify the actual product or service categories their firm serves before pursuing opportunities tagged to this code.